Dulaglutide and Cardiovascular and Heart Failure Outcomes in Patients With and Without Heart Failure: A Post-hoc Analysis from the REWIND Randomized Trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F22%3A10446955" target="_blank" >RIV/00064203:_____/22:10446955 - isvavai.cz</a>

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Y53_0bBAUP" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Y53_0bBAUP</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ejhf.2670" target="_blank" >10.1002/ejhf.2670</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Dulaglutide and Cardiovascular and Heart Failure Outcomes in Patients With and Without Heart Failure: A Post-hoc Analysis from the REWIND Randomized Trial

Popis výsledku v původním jazyce

AIMS: People with diabetes are at high risk for cardiovascular events including heart failure. We examined the effect of the glucagon-like peptide 1 agonist dulaglutide on incident heart failure events and other cardiovascular outcomes in those with or without prior heart failure the randomized placebo-controlled Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial (ClinicalTrials.gov number NCT01394952). METHODS AND RESULTS: The REWIND major adverse cardiovascular event (MACE) outcome was the first occurrence of a composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes (including unknown causes). In this post-hoc analysis, a heart failure event was defined as an adjudication-confirmed hospitalization or urgent evaluation for heart failure. Of the 9901 participants studied over a median follow-up of 5.4 years, 213/4949 (4.3%) randomly assigned to dulaglutide and 226/4952 (4.6%) participants assigned to placebo experienced a heart failure event (HR 0.93, 95% CI 0.77- 1.12; P=0.46). In the 853 (8.6%) participants with heart failure at baseline, there was no change in either MACE or heart failure events with dulaglutide as compared to participants without heart failure (p=0.44 and 0.19 for interaction, respectively). Combined CV death and heart failure events were marginally reduced with dulaglutide compared to placebo (HR 0.88, 95% CI: 0.78-1.00; p=0.050) but unchanged in patients with and without heart failure at baseline (p=0.31). CONCLUSIONS: Dulaglutide was not associated with a reduction in HF events in patients with type 2 diabetes regardless of baseline HF status over 5.4 years of follow up.

Název v anglickém jazyce

Dulaglutide and Cardiovascular and Heart Failure Outcomes in Patients With and Without Heart Failure: A Post-hoc Analysis from the REWIND Randomized Trial

Popis výsledku anglicky

AIMS: People with diabetes are at high risk for cardiovascular events including heart failure. We examined the effect of the glucagon-like peptide 1 agonist dulaglutide on incident heart failure events and other cardiovascular outcomes in those with or without prior heart failure the randomized placebo-controlled Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial (ClinicalTrials.gov number NCT01394952). METHODS AND RESULTS: The REWIND major adverse cardiovascular event (MACE) outcome was the first occurrence of a composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes (including unknown causes). In this post-hoc analysis, a heart failure event was defined as an adjudication-confirmed hospitalization or urgent evaluation for heart failure. Of the 9901 participants studied over a median follow-up of 5.4 years, 213/4949 (4.3%) randomly assigned to dulaglutide and 226/4952 (4.6%) participants assigned to placebo experienced a heart failure event (HR 0.93, 95% CI 0.77- 1.12; P=0.46). In the 853 (8.6%) participants with heart failure at baseline, there was no change in either MACE or heart failure events with dulaglutide as compared to participants without heart failure (p=0.44 and 0.19 for interaction, respectively). Combined CV death and heart failure events were marginally reduced with dulaglutide compared to placebo (HR 0.88, 95% CI: 0.78-1.00; p=0.050) but unchanged in patients with and without heart failure at baseline (p=0.31). CONCLUSIONS: Dulaglutide was not associated with a reduction in HF events in patients with type 2 diabetes regardless of baseline HF status over 5.4 years of follow up.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Heart Failure

ISSN

1388-9842

e-ISSN

1879-0844

Svazek periodika

24

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

8

Strana od-do

1805-1812

Kód UT WoS článku

000855362000001

EID výsledku v databázi Scopus

2-s2.0-85138346552